The approval is based on data from the randomized, open-label, phase 3 OlympiAD trial, which tested Lynparza versus chemotherapy in patients with a confirmed BRCA mutation. Lynparza was found to significantly prolong progression-free survival compared with chemotherapy, reducing the risk of disease progression or death by 42%.
Lynparza, a first-in-class PARP inhibitor, potentially exploits DNA damage response pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells. Specifically, in vitro studies have shown that Lynparza-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage and cancer cell death.
AstraZenica believes that the future of treatment for many diseases lies in uncovering mechanisms that are newly emerging or are still to be discovered. The company is focused on breakthrough science to discover these mechanisms and develop novel, targeted therapies that interact with them.
Merck provides healthcare solutions worldwide through four segments: pharmaceutical, animal health, healthcare services, and alliances. The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project